The annual number of medtech acquisitions is on course to slump to its lowest level since 2017, Needham analysts say. At the midpoint of the year, deal volumes are down but values are up. The analysts see the potential for increased activity, citing stabilizing interest rates and low valuations. Still, they identified antitrust concerns as a barrier that could persist until at least the presidential election. Needham analysts removed Nevro from their list of the top 25 potential acquisition targets due to its “modest growth rate.” Neuropace, Zimvie, Artivion and Masimo joined the list to replace Nevro and companies that are part of deals, such as Shockwave Medical and Silk Road Medical.
Read the full article: Medtech M&A May Pick Up after Mixed Start to 2024: Analysts //
Source: https://www.medtechdive.com/news/medtech-deals-may-pick-up-2024-needham/720255